Overview
Many people who suffer from gout still struggle with symptoms because they cannot tolerate or take common treatments like allopurinol or uricase. A gout clinical trial is testing the effectiveness and safety of the study drug dotinurad at lowering serum uric acid (the waste product that builds up in the blood, leading to gout symptoms).
Sign up below to learn more about this gout clinical trial!
About the Study
This gout clinical trial is testing the safety and effectiveness of dotinurad compared with a placebo at lowering serum uric acid—the waste product that causes gout symptoms—in people who still have flare-ups but CANNOT take allopurinol or febuxostat, or for whom intravenous (IV) uricase treatment did not help.
You will also be given colchicine or a nonsteroidal anti-inflammatory drug (NSAID) to prevent gout flares.
Joining this study is entirely voluntary (which means that participation is completely up to you). If you choose not to take part in this study, it will not impact your current medical care now or in the future. If you participate, you can decide to leave the study at any time and for any reason.
Who Can Join
You may be able to join this gout clinical trial if you:
- Are 18 to 75 years of age
- Have been diagnosed with gout for at least 1 year
- Still have gout flare-ups and either:
- Are unable to take allopurinol or febuxostat
- OR− IV uricase treatment was not effective
*You will need to meet other requirements to join the study.
Not sure if you qualify for this gout clinical trial? That’s okay.
A member of our recruitment team will review your medical history and medications with you to see if this study may be right for you. You may also view qualify for other studies.
What to Expect
Your participation will last around 44 weeks (about 11 months) and involves 15 study visits.
- Screening (4 weeks)
You will answer questions about your health and have tests to see if the study is right for you.
- Treatment Period 2 (12 weeks)
Participants in the dotinurad group will continue to take dotinurad.
Participants in the placebo group will switch to dotinurad.
- Treatment Period 1 (24 weeks)
Participants will receive either 1 of 3 dotinurad doses or placebo.
- Follow-up (4 weeks)
Participants will be checked for the effects of treatment and any side effects. Those who finish treatment may join an optional long-term extension study if eligible after completing Treatment Period 2.